Sign In
Buy TRIB
$11.60
-1.15 (-9.02%)
At Close: Jul 31, 2026
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
04:05pm, Monday, 09'th Sep 2024
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includi
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
09:55am, Tuesday, 03'rd Sep 2024
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inclu
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
04:05pm, Monday, 26'th Aug 2024
DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includin
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
05:00pm, Tuesday, 20'th Aug 2024
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript
03:43am, Friday, 16'th Aug 2024
Trinity Biotech plc (NASDAQ:TRIB ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Simon Dunne
Trinity Biotech Announces Q2 2024 Financial Results
07:30am, Wednesday, 14'th Aug 2024
-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business-
Trinity Biotech to Announce Q2 2024 Financial Results
04:05pm, Tuesday, 13'th Aug 2024
Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
04:05pm, Tuesday, 06'th Aug 2024
DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
09:24am, Friday, 02'nd Aug 2024
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth-
Trinity Biotech Announces Appointment of A New CFO
04:05pm, Tuesday, 09'th Jul 2024
DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
07:00am, Monday, 24'th Jun 2024
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
09:10am, Monday, 10'th Jun 2024
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostic
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
04:00am, Monday, 03'rd Jun 2024
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript
06:44pm, Thursday, 23'rd May 2024
Trinity Biotech plc (NASDAQ:TRIB ) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald -
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
08:00am, Thursday, 23'rd May 2024
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-
